glp-1 neuroinflammation Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders GLP-1 programs the neurovascular landscape:

Mutations in CPT1 can cause carnitine palmitoyltransferase I (CPT I) deficiency, which is an autosomal recessive genetic condition (need two copies of the mutation)

We manage antidepressants, mood stabilizers, antipsychotics, anxiolytics

Secondary and exploratory endpoints will evaluate a range of additional safety and efficacy measures, including the percentage of patients who achieve 5%, 10%, 15%, and 20% body weight reduction

The commercial success of any weight loss therapeutic will depend heavily on patient acceptability and adherence, making oral, long-acting depot, and other non-injectable options critical pipeline priorities rather than nice-to-have features

Learning how GLP-1 works can help you understand why your weight loss changes take place gradually, and why progress may look different from one person to another

Kylee breaks down what the research actually shows for the big-name peptides, why "thousands of patients swear by it" is not evidence, and what she tells athletes who ask whether BPC-157 will fix their tendons faster